Scientists have long sought to target the interaction between the proteins p53 and Mdm2 in tumor cells, but their interaction in immune cells may be just as important.

Patients with cancers of unknown origin greatly benefited from next-generation sequencing; widespread inherited cancer risk also suggests broad utility, a study finds.

As large multi-cancer datasets become more important for predicting who may benefit from cancer drugs, a new approach better accounts for potentially overlooked variation.

Targeting this inside-the-cell checkpoint could potentially improve response to cancer immunotherapy.

Engineers and oncologists teamed to develop a microfluidic chip capable of capturing the body’s natural killer immune cells to harvest their cancer-killing exosomes.

A new understanding of intracellular pathways activated as T cells start to mount an immune response offers clues against graft-versus-host disease, a serious complication of bone marrow transplantation.